16.8: Translating a Laboratory Finding into Clinical Evidence

Cell Culture Textbook (Biot 77 IVC) · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-NC-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    16.8: Translating a Laboratory Finding into Clinical Evidence

    Translation is the process of developing research findings into translation.png useful applications, including potential medical interventions. It involves defining a product or intervention, testing its relevant properties, and gathering evidence in models and people as appropriate. Development is iterative: a later finding can require a change to the product, process, assay, or study design.

    Nonclinical studies investigate a proposed intervention outside human clinical trials. Relevant questions include whether the material reaches the intended site, how long it persists, what biological effects it has, and what harms it could cause. The study program should reflect the product and its proposed use. A model that cannot respond to a human cell product may be poorly suited to evaluate its intended activity.

    For stem cell-derived products, uncontrolled growth, unwanted differentiation, or remaining undifferentiated cells can raise concerns. The cells' source, processing, genetic modification, and persistence all influence the assessment. Autologous origin does not remove those risks. ISSCR guidance emphasizes a product-specific evaluation of nonclinical safety and potential benefit.

    A clinical trial studies an intervention in people according to a protocol. Early trials often emphasize safety, feasibility, and selection of a suitable dose or regimen. Later studies evaluate benefit and risks in the intended patient group. Trials can combine or adapt phases, and cell and gene therapy development may require designs suited to small populations or product-specific features.

    Efficacy refers to the ability of an intervention to produce the intended benefit under the study conditions. Choose an endpoint that addresses a meaningful question. A change in a molecular marker may help explain activity, but it is not automatically evidence of improved function or health.

    Illustration

    Worked example: the next question after faster gap closure

    A controlled experiment finds greater NHDF gap closure after exposure to an EV-enriched preparation. This supports a statement about the measured culture endpoint under those conditions. Before proposing a clinical effect, the team needs to define the preparation and evaluate alternative explanations. Cell division, migration, cell loss, soluble components, and changes in image analysis can influence closure. Follow-up work should determine which explanation the evidence supports. A claim about wound healing would additionally require appropriate evidence about tissue responses, delivery, quality, safety, and clinical outcomes.

    Attribution: Images AI-generated using ChatGPT Modified by Emalee Mackenzie, Irvine Valley College. Licensed under CC BY-NC-SA


    This page titled 16.8: Translating a Laboratory Finding into Clinical Evidence was last modified on Wed, 21 Oct 2026 01:35:46 GMT and is shared under a CC BY-NC-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.